The global cancer biopsy market size is evaluated at USD 36.55 billion in 2025, and it is forecasted to surpass over USD 172.29 billion by 2034, representing a CAGR of 18.80% from 2025 to 2034.
According to Precedence Research, the worldwide cancer biopsy market revenue was valued at $30.77 billion in 2024. The increasing prevalence of cancer and demand for personalized medicines are majorly anticipating global market growth. The market is further expanding due to rising demand for minimally invasive procedures and technological advancements in biopsy.
This Report is Readily Available for Immediate Delivery | Download the Sample Pages of this Report@ https://www.precedenceresearch.com/sample/1514
Cancer Biopsy Market Key Points
• North America led the global market by holding the largest market share of 47% in 2024.
• The tissue biopsy segment is estimated to capture the biggest market share in 2024.
• The liquid biopsy segment is anticipated to grow at a fastest CAGR between 2025 and 2034.
• The kits and consumables segment predicted to register the highest market share of 61% in 2024.
• The breast cancer segment is estimated to hold the highest market share in 2024.
Market Overview and Industry Potential
The prevalence of cancer, including tumor cancer, breast cancer, colorectal cancer, lung cancer, cervical cancer, and other applications, is rapidly rising around the globe, making it essential for more adoption of a cancer biopsy. The cancer biopsy market is witnessing growth due to the rising incidence of cancer, growing awareness of the inheritance of oncology disorders, and technology advancements. Increased demand for personalized medicines is leading to further technology advancements.
Awareness of genetic testing is playing a major role in ongoing advancements in biopsy procedures and effectiveness. Furthermore, Technological advancements like genetic testing, liquid biopsy, AI integration, and next-generation sequencing are transforming the accuracy, access, and cost-effectiveness of cancer biopsy worldwide. Ongoing innovations and advancements in liquid biopsy and a surge in cutting-edge technology implementation are projected to open novel opportunity doors for the cancer biopsy market.
Set up a meeting at your convenience to get more insights instantly! https://www.precedenceresearch.com/schedule-meeting
Influence of Artificial Intelligence (AI) on Diagnostics and Treatment in Oncology
The integration of artificial intelligence in cancer biopsy is a major step in the transformation of the market. AI in cancer biopsy is surging for more accuracy, speed, and efficiency in cancer detection and diagnosis strategies. AI-enabled image analysis helps detect accurate patterns and reduce false negatives. AI is enabled to provide early detection of cancer inheritance by analyzing patient medical history.
AI algorithms can provide cancer risk rates by analyzing the genetic data of the patient. AI integration has not only provided advancements in biopsy but also enabled accessibility of remote analysis, expanding testing capabilities, and personalized medicines. AI is projected to drive spectacular growth in the global cancer biopsy market in the upcoming years.
Key Market Trends
Growing Awareness of Genetic Testing
The rising prevalence of cancer disease is driving demand for personalized medicines to treat an individual patient based on their genetic profile with a high genetic risk of cancer. Awareness of genetic testing is driving a shift towards targeted biopsies. Genetic testing enables the provision of personalized medicine plans and reduces unnecessary biopsies. The need for early cancer detection and preventative measurements is a major instance driving the adoption of genetic testing.
Government education programs for cancer prevention, awareness among healthcare professionals, patient engagement and education, and digital marketing strategies to be aware of the Accessibility and cost of genetic testing are likely to transform the cancer biopsy market in the upcoming period.
Screening Program
The rising awareness of inherited oncology disorders is driving demand for early detection and diagnosis. The need for cancer screening led to screening programs. This program enables underserved populations to access cancer screening. This program furthers the rising adoption of liquid biopsy, a non-invasive and affordable biopsy. Government and regulatory investments in healthcare infrastructures allow the promotion of screening programs to provide early detection and diagnosis access, reduce mortality rates, and enhance patient engagement.
Cancer Biopsy Market Report Coverage
|
Report Coverage |
Details |
|
Market Size in 2025 |
USD 36.55 Billion |
|
Market Size in 2024 |
USD 30.77 Billion |
|
Market Size by 2034 |
USD 172.29 Billion |
|
CAGR from 2025 to 2034 |
18.80% |
|
Leading Region |
North America |
|
Fastest Growing Region |
Asia Pacific |
|
Base Year |
2024 |
|
Forecast Period |
2025 to 2034 |
|
Segments Covered |
Type, Product, Application, and Regions |
|
Regions Covered |
North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa |
For questions or customization requests, please reach out to us @ sales@precedenceresearch.com | +1 804 441 9344 Key Regions Analysis: U.S. Cancer Biopsy Market Size to Worth USD 50.60 Bn by 2034 The
U.S. cancer biopsy market size was valued at USD 8.87 billion in 2024 and is
projected to be worth around USD 50.60 billion by 2034, growing at a CAGR of
19.02% from 2025 to 2034. North
America dominates the global cancer biopsy market with key factors, including
well-established healthcare infrastructure, the prevalence of cancer, and the
adoption of advanced technologies. Advancements in healthcare infrastructure
allow access to cutting-edge diagnostics technologies and skilled healthcare
professionals. The
United States is leading the regional market by contributing the highest share.
High cancer prevalence in the country is the key factor contributing to the
country's market expansion. The United States has witnessed a high demand for personalized
medicines and minimally invasive biopsy procedures, which has led
countries to broad focus on innovation and developments of target therapies and
MRI-guided biopsy technology. Canada is the second largest country in the leading
regional market due to the high adoption rate of minimally invasive biopsy
procedures. • In
2025, the United States reported 2,041,910 new cancer cases and 618,120 cancer
deaths projections. Cancer mortality rate reducing through 2022 by 4.5 million
deaths since 1991 due to smoking declines and adoption of early cancer
detective tools and technologies. Asia
Pacific accounted for significant growth in the forecast period, with an increased
prevalence of cancer in the region. The prevalence of breast cancer is topping
in the region. The high adoption rate of liquid biopsy in Japan and China is
the major factor leading Asia to boost the market. A large aging population,
government initiatives, and expanding healthcare infrastructure are major
factors influencing Asia's use of cancer biopsy. Countries
like China, India, Japan, Australia, and South Korea are significantly fueling
the market growth in Asia. China is leading the regional market due to
expanding liquid biopsy, needle biopsy, and breast cancer liquid biopsy. Japan
contributes to the market growth as a country with a significant aging
population and substantial government investments. On the other hand, India is
driving significant market growth, majorly due to government and regulatory
initiatives for cancer awareness and investments and funding for advancing
healthcare infrastructure. • In
January 2025, Smt Droupadi Murmu, The President of India, inaugurated KLE
Cancer Hospital at Belagavi, Karnataka. This step of the
president aimed to spread more awareness of the causes, diagnosis, and
treatment of cancer. Cancer Biopsy Market Segmentation Analysis Type Analysis The
tissue biopsy segment generated a major share of the cancer biopsy market in
2024 due to increasing tissue cancer prevalence and advancements in biopsy
technologies. Tissue biopsy is considered the gold standard for cancer
diagnosis. Sophisticated tissue biopsy methods are reducing in the market due
to the increased adoption of personalized medicines. Rising awareness of tissue
cancers and regulatory initiatives are driving the segment. • In
January 2025, the FDA issued a draft guidance with the Office for Human
Research Protections offering recommendations for including tissue biopsies as
part of clinical trials once it is finalized. This guidance assists industry,
clinical investigators, and institutions in knowledge considerations for tissue
biopsies in adults and children in clinical trials. The liquid biopsy segment
is projected to grow significantly over the predicted years because of the
increased incidence of tumors. The rapidly growing prevalence of tumors is
expected to drive liquid biopsies to become routine in clinics. Rising demand
for minimally invasive biopsy procedures to reduce recovery time and pain is
driving the adoption of liquid biopsy in healthcare infrastructure. Product Analysis The
kit and consumables segment dominated the cancer biopsy market due to the
increased adoption of kits and consumables for effective screening and
diagnosis solutions. Advancement in needles and specialized collection
containers helps to improve the efficiency and accuracy of cancer biopsies. Key
manufacturing companies are leveraging broad investment in manufacturing
advanced kits and consumables. • In
November 2024, Roche announced the launching of a fully automated version of
its tissue-based comprehensive genomic profiling (CGP) sequencing kit to enable
translational oncology researchers to achieve library preparation and target
enrichment in about 24 hours with only 3.5 hours of hands-on time. On the other hand,
the instruments segment is projected to witness significant growth in the
forecast period, with a rising focus on advancing instruments for cancer
biopsy. Technology advancements are surging the demand for advanced biopsy
diagnostic tools. Additionally, increased demand for minimally invasive
procedures and personalized medicines are leveraging opportunities in advancing
instruments. Application Analysis The
breast cancer segment leads the cancer biopsy market. This growth is attributed
to the increased incidence of breast cancer in women worldwide. Advancements in
technology like MRI and digital mammography enable improved accuracy of breast
cancer biopsy. The demand for specialized and sensitive biopsy instruments is
trending for accurate and efficient screening. The need for minimally invasive
biopsy procedures is gaining popularity for breast cancer diagnosis. The
prostate cancer segment will grow significantly due to the rising incidence of
prostate cancer in men. The demand for prostate biopsy is taking place for
diagnosis and monitoring. The utilization of Prostate prostate-specific antigen
(PSA) testing for screening often leads to a large number of biopsies. Demand
for early detection and personalized medicines have driven focus on the
development of target therapies and MRI-guided biopsies technology. Browse More Insights: 🔸Cancer Diagnostics Market:
https://www.precedenceresearch.com/cancer-diagnostics-market 🔸Liquid Biopsy Market: https://www.precedenceresearch.com/liquid-biopsy-market 🔸Biopsy Devices Market: https://www.precedenceresearch.com/biopsy-devices-market 🔸Fusion Biopsy Market: https://www.precedenceresearch.com/fusion-biopsy-market 🔸Biopsy Needle Market: https://www.precedenceresearch.com/biopsy-needle-market 🔸Solid Tumor Cancer
Treatment Market: https://www.precedenceresearch.com/solid-tumor-cancer-treatment-market 🔸Cancer Therapeutics and
Biotherapeutics Market: https://www.precedenceresearch.com/cancer-therapeutics-and-biotherapeutics-market 🔸Non-Invasive Cancer
Diagnostics Market: https://www.precedenceresearch.com/non-invasive-cancer-diagnostics-market 🔸Artificial Intelligence
(AI) In Oncology Market: https://www.precedenceresearch.com/artificial-intelligence-in-oncology-market Cancer Biopsy Market Key Players •
QIAGEN •
Guardant Health Inc. •
Exact Sciences Corporation •
Agena Bioscience Inc. •
Personal Genome Diagnostics Inc. •
ANGLE plc •
BD (Becton, Dickinson, and Company) •
Myriad Genetics, Inc. •
Hologic, Inc. •
Biocept, Inc. •
Thermo Fisher Scientific, Inc. •
Danaher Global News • In
October 2024, researchers at the University of Rochester developed
catch and display for liquid biopsy (CAD-LB), a new method for using ultrathin
membranes to easily identify EVs for rapid liquid biopsies. This method holds
promise for diagnosing cancer quickly and cost-effectively. • In
September 2024, Reliance Industries Limited’s subsidiary Strand Life
Sciences launched its Somatic Advantage 74 Liquid Biopsy (SA74 LB) Test for the
detection of circulating tumor DNA in blood samples of cancer patients to
provide a comprehensive analysis of 74 clinically relevant genes and provides
invaluable insights for cancer treatment. •In March 2024, Mammotome
received the Food and Drug Administration 510(k) clearance for its new
LumiMARKTM Biopsy Site Marker, a tissue marker line designed with
visibility at the top of mind. This marker is distinct from each angle under
ultrasound, mammography, and magnetic resonance. Cancer Biopsy Market Segment Covered in the Report By Product •
Instruments •
Kits and Consumables •
Services By Type • Tissue
Biopsies
o Fine Needle Aspiration (FNA)
o Core Needle Biopsy (CNB) • Liquid
Biopsies • Others By Application •
Breast Cancer •
Colorectal Cancer •
Cervical Cancer •
Lung Cancer •
Prostate Cancer •
Skin Cancer •
Blood Cancer •
Kidney Cancer •
Liver Cancer •
Pancreatic Cancer •
Ovarian Cancer •
Others By Geography • North
America
o U.S.
o Canada
o Mexico • Europe
o U.K.
o Germany
o France • Asia-Pacific
o China
o India
o Japan
o South Korea • Latin
America
o Brazil
o Rest of Latin America • Middle
East and Africa (MEA)
o GCC
o North Africa
o South Africa
o Rest of the Middle East and Africa Immediate Delivery Available | Buy This Premium Research Report@ https://www.precedenceresearch.com/checkout/1514 You can place an order or ask any questions, please feel free to contact
at sales@precedenceresearch.com | +1 804 441 9344 Precedence
Research offers exclusive subscription services designed to provide in-depth
data and analytics insights. With a subscription, you gain access to a
comprehensive suite of statistical resources, market intelligence, and research
tools tailored to your business needs. Whether you're looking for industry
trends, competitive analysis, or future market projections, our subscription
plans ensure you stay ahead with reliable, up-to-date information. Browse Our Subscription Plans@ https://www.precedenceresearch.com/get-a-subscription About Us Precedence
Research is a worldwide market research and consulting organization. We give an
unmatched nature of offering to our customers present all around the globe
across industry verticals. Precedence Research has expertise in giving
deep-dive market insight along with market intelligence to our customers spread
crosswise over various undertakings. We are obliged to serve our different
client base present over the enterprises of medicinal services, healthcare,
innovation, next-gen technologies, semi-conductors, chemicals, automotive, and
aerospace & defense, among different ventures present globally. Web: https://www.precedenceresearch.com Our Blogs: Towards
Healthcare | Towards
Packaging | Statifacts | Towards EV Solutions | Towards Dental | Towards Automotive | Nova One Advisor For Latest Update Follow Us: 
